# INTerpath-009: HCP commentary report

> 82 verified statements (14 from clinicians verified by NPI or staff page) from 18 commentary sources · 7 findings · updated Oct 31, 2026

## Report

- Trial: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
- NCT ID: NCT06623422
- Registry: https://clinicaltrials.gov/study/NCT06623422
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: intismeran autogene (V940) plus pembrolizumab
- Indication: resectable stage II–IIIB (N2) NSCLC not achieving pCR
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: f3f2079f0e45bbee7431195032a22622d5b21b5d9ca111e781bef9ef74c941f6

## Counts

- HCP commentary sources screened: 46
- Sources cited by verified statements: 19
- Verified statements: 82
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 14
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 12
- Voices cited: 10
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

INTerpath-009 asks whether adding intismeran autogene to postoperative pembrolizumab prolongs disease-free survival in patients with resected non-small-cell lung cancer and residual disease after neoadjuvant chemo-immunotherapy. Commentary comes from X and Bluesky posts, a podcast and YouTube videos. Debate centers on whether melanoma findings translate to lung cancer and whether vaccination adds benefit after neoadjuvant immunotherapy. Enthusiasm focuses on research enrollment, not routine-care availability.

## Open Medical Affairs question

What evidence would establish incremental postoperative value after prior chemo-immunotherapy while distinguishing vaccine tolerability, checkpoint toxicity and feasible research access?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Melanoma provides encouragement, but prior IO exposure and residual disease make lung-specific benefit an open question
- F2. The central controversy is incremental value: an alternative to neoadjuvant IO, or a treatment after it?
- F3. Safety reassurance is vaccine-specific and largely melanoma-based; systemic checkpoint toxicity remains a separate concern
- F4. Non-pCR enrichment is framed as a high-need immune-rescue experiment, sometimes with stronger biological conclusions than the evidence establishes
- F5. MRD-based escalation adds a related selection question without establishing who benefits from the vaccine
- F6. Manufacturing speed, consistency and geography are presented as conditions for practical access
- F7. Enthusiasm is directed toward research enrollment and awareness, not routine-care availability

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 11 | 7 | 6 | 5 | recorded | 6 |
| F2 | 9 | 10 | 3 | 5 | recorded | 3 |
| F3 | 14 | 17 | 1 | 0 | recorded | 3 |
| F4 | 23 | 24 | 5 | 2 | none recorded | 4 |
| F5 | 3 | 1 | 1 | 1 | none recorded | 4 |
| F6 | 12 | 9 | 1 | 0 | none recorded | 3 |
| F7 | 13 | 12 | 8 | 5 | none recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 3 | 4 | 0 | 0 | 4 | 11 | 3 | 6 posts and articles | yes |
| F2 | 3 | 4 | 0 | 1 | 1 | 9 | 5 | 3 posts and articles | yes |
| F3 | 9 | 1 | 0 | 1 | 3 | 15 | 6 | 1 podcast or video | yes |
| F4 | 17 | 1 | 0 | 1 | 4 | 25 | 1 | 2 posts and articles, 2 podcasts and video, 1 registry | yes |
| F5 | 0 | 1 | 0 | 0 | 2 | 3 | 1 | 1 post or article | yes |
| F6 | 6 | 0 | 0 | 2 | 4 | 14 | 3 | 1 podcast or video | yes |
| F7 | 8 | 0 | 1 | 0 | 4 | 13 | 2 | 5 posts and articles, 3 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Disease-Free Survival (DFS): F4 (2 shared claims)
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (5 shared claims), F4 (13 shared claims), F7 (2 shared claims)
- The comparison: F2 (2 shared claims), F4 (2 shared claims), F7 (1 shared claims)
- Safety and tolerability: F3 (14 shared claims)
- Design and conduct: F2 (2 shared claims), F4 (2 shared claims), F7 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. The central controversy is incremental value: an alternative to neoadjuvant IO, or a treatment after it?

An X post asks which treatment comparison would assess the vaccine’s contribution and whether INTerpath-009 addresses that question.

Source: X thread, 2026-10-23.

### F4. Non-pCR enrichment is framed as a high-need immune-rescue experiment, sometimes with stronger biological conclusions than the evidence establishes

A podcast discussion asks why INTerpath-009 enrolls patients with residual tumor after preoperative treatment.

Source: podcast, 2026-09-09.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 82 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 19 | Counts free |
| Speaker attribution for cited voices | 10 | Paid |

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Disease-Free Survival (DFS) | discussed | 2 | 1 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 20 | 7 |
| The comparison | discussed | 5 | 4 |
| Safety and tolerability | discussed | 14 | 1 |
| Design and conduct | discussed | 5 | 4 |
| Melanoma-to-lung translation and standards for lung-specific evidence | discussed | 16 | 8 |
| Incremental value, sequencing and fair comparisons | discussed | 15 | 5 |
| MRD-informed escalation in early-stage NSCLC | discussed | 3 | 1 |
| Individualized manufacturing, turnaround and global delivery | discussed | 12 | 1 |
| Research access, recruitment, referral and fairness | discussed | 11 | 7 |
| Personalization and the proposed vaccine–checkpoint mechanism | discussed | 8 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 40 | 14 |
| Bluesky threads | 3 | 1 |
| YouTube | 2 | 2 |
| Podcasts | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2024-10-28 to 2026-10-25
- Cited window: 2024-10-28 to 2026-10-25
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
- Registry: NCT06623422 (https://clinicaltrials.gov/study/NCT06623422)
- Study IDs: V940-009 · 2023-506327-29-00 (EU CT) · U1111-1293-5814 (UTN) · INTerpath-009 (MSD) · jRCT2061240105 (jRCT)
- Sponsor: Merck Sharp & Dohme LLC
- Collaborators: ModernaTX, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 680 (estimated)
- Start: 2024-10-21 (actual)
- Primary completion: 2033-05-16 (estimated)
- Primary endpoint: Disease-Free Survival (DFS) (Up to ~97 months)
- Intervention: Pembrolizumab (biological)
- Intervention: Cisplatin (drug)
- Intervention: Carboplatin (drug)
- Intervention: Pemetrexed (drug)
- Intervention: Gemcitabine (drug)
- Intervention: Paclitaxel (drug)
- Intervention: Intismeran autogene (biological)
- Intervention: Placebo (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 60 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This report describes the sources reviewed for this edition, not all HCP views or their prevalence; source and repost counts must not be read as independent clinician counts.
- No INTerpath-009 efficacy or safety result is provided in the statements. Melanoma efficacy references and KEYNOTE-942 safety figures cannot establish benefit or safety in the target NSCLC population.
- A full protocol and an exact-trial results publication were not available for this report, and only part of the intervention-related regulatory material was reviewed.
- Some surrounding discussion of perioperative and neoadjuvant evidence in resectable NSCLC, biomarker testing, specialist capacity and equitable access is not fully represented. This limits the account of the clinical and implementation rationale accompanying cross-study questions.
- Surrounding melanoma discussion of patient suitability, neoadjuvant feasibility, manufacturing attrition, generalisability, neoantigen validation, control selection and unresolved overall survival is also incomplete; the report should not be read as a complete appraisal of those melanoma studies.
- Speakers in the podcast and short videos are unnamed. Publisher names, account identities and professional profiles do not establish who spoke those passages.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Post dates locate the commentary, not a session or readout. Apart from the explicit clarification within the a speaker–another speaker exchange, dates do not establish changes of mind.
- Mechanistic, manufacturing and commercial-viability assertions remain attributed views; no comparative evidence is supplied to validate immune-rescue explanations, manufacturing uniformity or broad equitable access.
- No specific interpretation of the listed secondary endpoints was identified in the material reviewed; this does not establish that such discussion does not exist elsewhere.
- Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, capacity, and access barriers in resectable lung cancer.
- Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, specialist-capacity and equitable-access barriers in resectable NSCLC.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition, corrected 2026-10-31
  - Correction 2026-10-31: Corrected to match the delivered report: the limitations; the sample findings; the report description.

Last checked for new commentary 2026-10-31. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (82 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/interpath-009-nct06623422
- Agents: POST https://www.erudio.com/api/orders with {"report": "interpath-009-nct06623422", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=interpath-009-06623422

## Cite

Erudio Health. INTerpath-009 (NCT06623422): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/interpath-009-nct06623422

## Machine access

- JSON: https://www.erudio.com/reports/interpath-009-nct06623422.json
- Markdown: https://www.erudio.com/reports/interpath-009-nct06623422.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "interpath-009-06623422"}`